Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAM50 HER2-enriched subtype as predictor of response to neoadjuvant lapatinib plus trastuzumab in HER2-positive breast cancer
2013-001036-22Phase 2Completed
- Sponsor
- SOLTI
- Start
- Jul 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lapatinib and trastuzumab in breast cancer (2 arms), sponsored by SOLTI. Started Jul 2013; status: completed.
02
Drugs
lapatinibtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-001036-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001036-22.